Northleaf Appoints Shane Feeney to Lead and Expand Its Well-established Global Secondaries Business
Northleaf Capital Partners (Northleaf) today announced that Shane Feeney has joined the firm as Global Head of Secondaries, based in Toronto.
In this role, Feeney will oversee all aspects of Northleaf’s secondaries program, building on the firm’s highly successful 18-year track record in global secondary investing and enhancing existing team capabilities as the secondaries market continues to expand rapidly.
Feeney most recently served as Senior Managing Director & Global Head of Private Equity at CPP Investments, one of the world’s largest institutional investors with $497.2 billion in assets under management as of March 31, 2021. In this role, Feeney led the teams responsible for CPP Investments’ direct private equity, Asia private equity, private equity funds and secondaries investments. Under Feeney’s leadership, CPP Investments’ private equity program assets under management grew by approximately $73.6 billion. In fiscal 2021, CPP Investments’ private equity program generated a net return of 36.3%.
“We’re excited that Shane is joining our team. He will have a significant and immediate impact on the continued growth and evolution of our secondaries business, as well as on our global private markets investment platform more broadly,” said Northleaf Managing Partner and Co-Founder Stuart Waugh. “We are delighted to attract a seasoned leader with proven principal investment experience and success in building global private equity teams and investment programs. We know Shane well – and he’s an ideal fit with our strategy, team and culture.”
To date, Northleaf has invested more than $3 billion across the full spectrum of secondary market transactions, leveraging the firm’s global private markets platform and long-standing private equity sponsor relationships for proprietary deal flow, due diligence information and insights.
Feeney said: “Northleaf is a world-class global private markets investment manager with extensive secondaries experience and a strong growth trajectory, particularly in light of its recent strategic partnership with Power Corporation affiliates Mackenzie Financial and Great-West Lifeco. I’m looking forward to working with everyone at Northleaf to build on the firm’s longstanding track record of developing innovative private equity and secondaries solutions for investors around the world.”
Feeney will report to Northleaf Managing Director and Co-Founder Michael Flood, who leads the firm’s global private equity program.
“Shane’s appointment is an important leadership addition for our firm and supplements the existing capabilities and skills of our integrated private equity team,” Flood said. “As GP-led continuation vehicles, single company secondaries and other structured transactions have become a greater part of the broader secondaries market, Shane’s principal investment expertise and leadership will complement our existing direct private equity strategy and team. We recognized early on that GP-led secondary transactions, especially single asset acquisitions, require differentiated investment skills in order to be successful as the secondary market continues to evolve.”
Feeney joined CPP Investments in 2010 from Bridgepoint Capital Ltd. in London. Prior to Bridgepoint, he was a partner and founding member of Hermes Private Equity’s direct investing business, until its transition to Bridgepoint in 2009. Previously, he was an Associate Director at Morgan Grenfell Private Equity in London and has served as a director of Livingston International, 99 Cents Only Stores, The Gates Corporation and Air Distribution Technologies. He holds a BA in economics from Dartmouth College and an MBA from INSEAD.
Northleaf is a leading global private equity investor with more than 20 years of experience and manages more than $9 billion of private equity commitments in pooled funds and separately managed accounts across three investment strategies: secondaries, directs and solutions. Northleaf’s secondaries program was launched in 2003 and has invested more than $3 billion across the full spectrum of private market secondary transaction types. The firm’s direct private equity strategy is led by Matt Shafer, Global Head of Direct Private Equity, based in New York, and has invested $1 billion in non-control direct investments alongside leading private equity sponsors, structured capital solutions for private equity-backed companies and single company secondary investments. Northleaf’s solutions program has raised more than $4 billion since inception in 2001 and specializes in building flexible investment programs that provide investors with access to the full spectrum of private equity strategies, sectors and geographies.
About Northleaf Capital Partners
Northleaf Capital Partners is a global private markets investment firm with US$16 billion in private equity, private credit and infrastructure commitments under management on behalf of public, corporate and multi-employer pension plans, endowments, foundations, financial institutions and family offices. Northleaf’s 150-person team, located in Toronto, Montreal, London, New York, Chicago, Menlo Park and Melbourne, is focused exclusively on sourcing, evaluating and managing private markets investments globally. Northleaf’s portfolio includes more than 400 active investments in 40 countries, with a focus on mid-market companies and assets. For more information on Northleaf, please visit www.northleafcapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets26.7.2021 22:05:00 CEST | Press release
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a partnership agreement with Biocon Biologics Ltd., to combat the ongoing COVID-19 crisis in southern Asia. Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON). Under the terms of the agreement, Adagio will provide Biocon with materials and know-how to manufacture and commercialize an antibody treatment based on ADG20 in India and additional select emerging markets. ADG20, Adagio’s lead product candidate, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. Unlike other antibody-based therapies specifically targeting SARS-CoV-2, ADG20 has demons
SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis26.7.2021 18:40:00 CEST | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC). The rapid development of PlexPrime® SARS-CoV-2 Genotyping* tests will support investigations and monitoring of the range of emerging and circulating SARS-CoV-2 VOC that have been linked to increased transmissibility, reduced vaccine efficacy, or other characteristics that may require specific public health actions.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005313/en/ SpeeDx unique technology excels in mutation detection applications and can readily be applied to variants reported in the SARS-CoV-2 sequence databases. Compatible with standard qPCR instrumentation, the PlexPrime® SARS-CoV-2 Genotyping research reagents can reduce the manual process of preparing positive samples for sequence analysis
V-Square Appoints Erik Norland as Head of Distribution26.7.2021 17:00:00 CEST | Press release
V-Square Quantitative Management (V-Square) has announced the hiring of Erik Norland as its Head of Distribution. A 20-year industry veteran with asset management, custody, and global markets expertise, Erik’s addition to the team bolsters our strong client-centric approach to deliver customized ESG solutions as we continue to build our reputation as a specialized global asset manager. He will lead the firm's sales, consultant relationship and client service functions across institutional, insurance and wholesale. Mr. Norland, based in Stockholm, will report to Mamadou-Abou Sarr, co-founder and President and will join the global leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005571/en/ Erik Norland, Head of Distribution (Photo: Business Wire) "Erik is a results-focused leader who brings excellent experience in distribution strategy and execution, sales management and client relationship roles. I had th
Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa26.7.2021 16:10:00 CEST | Press release
Today, BioNTech SE (“BioNTech”) announced the start of its Malaria project which aims at the development of a safe and highly effective malaria vaccine and the implementation of sustainable vaccine supply solutions on the African continent. The company’s project is part of a programme by the kENUP Foundation to accelerating the eradication of Malaria. This goal was out of reach so far, despite enormous financial and public health efforts of the global community. The scientific and entrepreneurial progress made during the COVID-19 pandemic raise hopes that a highly efficacious vaccine could soon help to eradicate Malaria. BioNTech aims to develop a safe and highly effective mRNA vaccine with durable protective immunity for prevention of malaria and disease associated mortality. To this end, BioNTech will assess multiple vaccine candidates featuring known Malaria targets such as the circumsporozoite protein (CSP), as well as new antigens discovered in the pre-clinical research phase. The
PPG to Expand Production Capacity for PPG ISENSE Gloss Beverage Can Coatings at Delaware, Ohio, Plant26.7.2021 15:02:00 CEST | Press release
PPG (NYSE:PPG) today announced that it is currently adding capacity for the production of overvarnish coatings for beverage can exteriors, including PPG ISENSE™ Gloss coatings, at its Delaware, Ohio, plant. PPG expects the addition of the Delaware plant’s new volume to existing overvarnish capacity at its Oak Creek, Wisconsin, packaging coatings facility will increase the company’s overall production of overvarnish coatings in the U.S. by 40%. “Beverage can manufacturers around the world are facing unprecedented demand for their products,” said Todd White, PPG general manager, U.S. and Canada, and global strategic accounts, packaging coatings. “With this added capacity, we are committed to helping them meet that demand while adding more security to their supply chain for beverage can coatings.” In addition to increasing supply chain security for its customers and the packaging industry, the Delaware plant will provide in-line analytical capabilities for enhanced batch consistency. “PPG
NET ZERO Leaders Summit (Japan Business Conference 2021) - Online Event From Wednesday, July 28 : Latest Information26.7.2021 15:00:00 CEST | Press release
Japan’s Ministry of Economy, Trade and Industry (METI) and the Japan External Trade Organization (JETRO) are pleased to announce the jointly organized “NET ZERO Leaders Summit (Japan Business Conference 2021)” to accelerate innovation in green investment and the realization of carbon neutrality. The event will take place from Wednesday, July 28, and will be held online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210726005389/en/ Entrance_Lobby_Image (Graphic: Business Wire) Main Program In the main program, panel discussions will be held between 15 leaders of global companies and organizations. In addition, Mr. SASAKI Nobuhiko, Chairman and CEO of the Japan External Trade Organization (JETRO), will present the opening remarks, Mr. TOKURA Masakazu, Chairman of KEIDANREN (Japan Business Federation), will present the keynote speech and Prime Minister SUGA Yoshihide and Minister of Economy, Trade and Industry KAJIYAMA Hirosh
ADM Accelerates Growth of Leading Global Alternative Protein Platform with Planned Acquisition of Sojaprotein26.7.2021 14:05:00 CEST | Press release
Global nutrition leader ADM (NYSE: ADM) announced today that it has reached an agreement to acquire Sojaprotein, a leading European provider of non-GMO soy ingredients. Established in 1977, Serbia-based Sojaprotein has sales into 65 countries, offering a wide array of non-GMO vegetable protein ingredients for an extensive list of European and global customers in the meat alternative, confectionary, protein bar, pharmaceutical, pet food, and animal feed segments. The company had more than $100 million in sales in 2020. “Thirty years ago, ADM invented the soy vegetable burger, giving rise to the plant-based protein segment. Today, alternative proteins represents one of our core growth platforms, and as this $10 billion global industry grows to $30 billion over the next decade, we are investing to expand our unparalleled capabilities,” said Leticia Gonçalves, ADM’s president of Global Foods. “The addition of Sojaprotein – the largest producer of plant-based protein in southern Europe – ad